Annual revenue rose from KRW 661.6 billion in 2022 to KRW 731 billion in 2023 (up 10.5%), KRW 812.2 billion in 2024 (up 11.1%) and KRW 926.9 billion in 2025 (up 14.1%), growing for three consecutive years from 2023 with 2025 as the largest year in the 2022 to 2025 span.
Operating profit fell from KRW 72.7 billion in 2022 to KRW 66.9 billion in 2023 (down 8.0%), then rose to KRW 80.4 billion in 2024 (up 20.3%) and KRW 96.6 billion in 2025 (up 20.1%), increasing for two consecutive years.
The operating margin moved from 11.0% in 2022 to 9.1% in 2023, 9.9% in 2024 and 10.4% in 2025, a recovery since the 2023 low. Profit attributable to owners of the parent was KRW 52.9 billion in 2022, KRW 47.2 billion in 2023 (down 10.8%), KRW 61.2 billion in 2024 (up 29.8%) and KRW 66 billion in 2025 (up 7.8%).
Net profit including non-controlling interests, which differs from the owner-attributable figure, was KRW 73.9 billion in 2025.
At the end of 2025, total equity stood at KRW 763.7 billion, of which KRW 663.7 billion belonged to owners of the parent, and total liabilities were KRW 299.2 billion, with the debt ratio easing from 44.7% in 2022 to 39.2%.
Operating cash flow was KRW 40.9 billion in 2022, KRW 76.1 billion in 2024 and KRW 68.8 billion in 2025.
On a quarterly basis, revenue moved from KRW 226.8 billion in the third quarter of 2025 to KRW 242.9 billion in the fourth quarter (up 7.1% quarter on quarter), then KRW 251 billion, KRW 258.9 billion and KRW 258.7 billion in the first three quarters of 2026, with the third quarter up 14.0% year on year.
Operating profit peaked at KRW 27.3 billion in the first quarter of 2026 and then fell to KRW 26.1 billion and KRW 23.8 billion, the third quarter down 4.1% year on year and the second consecutive quarterly decline.
Third-quarter selling and administrative expenses rose 18.5% to KRW 117.6 billion, outpacing revenue growth, while financing costs climbed from about KRW 532 million to KRW 9.24 billion and weighed on owner-attributable profit.
The gap between consolidated and parent-only growth came from the subsidiary DongKook Life Science, with January to September parent-only operating profit up 23.3% against 6.9% on a consolidated basis.